Reintroducing
About us / Press room
News about our community
Our actions match our words
October 15, 2018
ORTHO DERMATOLOGICS TO PRESENT NEW SCIENTIFIC DATA DURING THE FALL CLINICAL DERMATOLOGY CONFERENCE

16 Poster Presentations Include New Evaluations of Investigational and Existing Products

RALEIGH, N.C., Oct. 15, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced the presentation of 16 posters during the Fall Clinical Dermatology Conference in Las Vegas, Oct. 18-21. The presentations will feature new analyses of the investigational drug DUOBRII™1 (halobetasol propionate and tazarotene) (IDP-118) Lotion—including long-term evaluations of safety and maintenance of treatment success—as well as new data on SILIQ™ (brodalumab) injection, ALTRENO™ (tretinoin) Lotion, 0.05%, and BRYHALI™ (halobetasol propionate) Lotion, 0.01%, which received tentative approval from the U.S. Food and Drug Administration (FDA) on Oct. 8, 2018. Please see below for SILIQ boxed warning about suicidal ideation and behavior.

1 – Provisional Name

October 11, 2018
ORTHO DERMATOLOGICS ANNOUNCES PUBLICATION OF PIVOTAL PHASE 3 EFFICACY AND SAFETY DATA ON ALTRENOTM (TRETINOIN) LOTION, 0.05% IN THE JOURNAL OF DRUGS IN DERMATOLOGY

ALTRENO Lotion Provides Statistically Significant Greater Efficacy Over Vehicle with a Favorable Safety and Tolerability Profile in Two Pivotal Clinical Trials1

RALEIGH, N.C., Oct. 11, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology has published results of two identical Phase 3, multicenter, randomized, double-blind, vehicle-controlled, parallel group studies examining the efficacy and safety of ALTRENOTM (tretinoin) Lotion, 0.05%, the first formulation of tretinoin, a retinoid, in a lotion indicated for the topical treatment of acne vulgaris in patients 9 years of age and older.1 The U.S. Food and Drug Administration approved the New Drug Application for ALTRENO Lotion on Aug. 24, 2018.

October 8, 2018
ORTHO DERMATOLOGICS RECEIVES TENTATIVE FDA APPROVAL FOR BRYHALITM (HALOBETASOL PROPIONATE) LOTION, 0.01%, FOR PLAQUE PSORIASIS
IN ADULTS

In Clinical Trials, BRYHALI Lotion Demonstrated Significant Treatment Success Over Vehicle as Early as Week Two, Which Continued Through Week 12 (Four Weeks Post Treatment)1
New Corticosteroid Lotion Formulation with Safety Proven for Up to Eight Weeks Duration of Use1
Company Plans to Launch BRYHALI Lotion in November 2018 Upon Final FDA approval

RALEIGH, N.C., Oct. 8, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the U.S. Food and Drug Administration (FDA) has provided tentative approval of the New Drug Application for BRYHALITM (halobetasol propionate) Lotion, 0.01%, for the topical treatment of plaque psoriasis in adult patients. BRYHALI Lotion is a new potent to superpotent corticosteroid that contains 0.01 percent halobetasol propionate in a novel vehicle lotion. Its safety has been established in clinical trials with dosing for up to eight weeks with no increase in epidermal atrophy.1 The final FDA approval for BRYHALI Lotion is pending the expiration of exclusivity for a related product, which is expected in early November 2018. The company plans to launch BRYHALI shortly thereafter, as scheduled, in November 2018.

October 2, 2018
ORTHO DERMATOLOGICS ANNOUNCES PUBLICATION OF PIVOTAL PHASE 3 EFFICACY AND SAFETY DATA ON BRYHALITM (HALOBETASOL PROPIONATE) LOTION, 0.01% IN THE JOURNAL OF DRUGS IN DERMATOLOGY

Two Pivotal Trials Demonstrate the Efficacy of Investigational Drug BRYHALI Lotion Over Vehicle at Eight Weeks of Treatment, with Favorable Tolerability Profile1

RALEIGH, N.C., Oct. 2, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses, today announced that the Journal of Drugs in Dermatology has published results of two Phase 3 randomized controlled trials (Studies 1 and 2) examining the safety and efficacy of BRYHALITM* (halobetasol propionate) Lotion, 0.01%, an investigational potent to superpotent** corticosteroid, in the treatment of moderate-to-severe plaque psoriasis.1 BRYHALI Lotion has a Prescription Drug User Fee Act (PDUFA) action date of October 5, 2018.

August 29, 2018
FDA ACCEPTS RESUBMISSION OF NEW DRUG APPLICATION FOR DUOBRIITM1 (HALOBETASOL PROPIONATE AND TAZAROTENE) LOTION

RALEIGH, N.C., Aug. 29, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses in the world, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application (NDA) for DUOBRIITM1 (halobetasol propionate and tazarotene) (IDP-118) Lotion for the topical treatment of plaque psoriasis. The FDA accepted the application as a Class 2 resubmission, with a PDUFA action date of Feb. 15, 2019.

August 24, 2018
ORTHO DERMATOLOGICS RECEIVES FDA APPROVAL FOR ALTRENO™ (TRETINOIN 0.05%) LOTION FOR ACNE

RALEIGH, N.C., Aug. 24, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses in the world, today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for ALTRENOTM (tretinoin 0.05%) lotion, indicated for the topical treatment of acne vulgaris in patients 9 years of age and older. ALTRENO is the first formulation of a tretinoin in a lotion, and has been shown to be effective and generally well-tolerated.1 ALTRENO is expected to be available during the fourth quarter of 2018.

August 16, 2018
ORTHO DERMATOLOGICS RESUBMITS U.S. NEW DRUG APPLICATION FOR DUOBRIITM1 (HALOBETASOL PROPIONATE AND TAZAROTENE) LOTION

LAVAL, Quebec, Aug. 15, 2018 – Ortho Dermatologics, a division of Bausch Health Companies Inc. (NYSE/TSX: BHC), today announced it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for DUOBRIITM1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis.

August 8, 2018
ORTHO DERMATOLOGICS ANNOUNCES 2018 ASPIRE HIGHER SCHOLARSHIP RECIPIENTS

RALEIGH, N.C., August 8, 2018 – Ortho Dermatologics, one of the largest prescription dermatology health care businesses in the world, today announced the 2018 honorees of the Aspire Higher program, which since 2013 has granted more than $450,000 in scholarships to students who have been affected by dermatologic conditions. This year nine students will receive scholarships of $10,000 each to pursue graduate or undergraduate degrees at an accredited, nonprofit, two- or four-year college, university, or advanced (post-high school) vocational or technical school.

July 11, 2018
ORTHO DERMATOLOGICS ANNOUNCES LAUNCH OF MOBILE APP DESIGNED TO HELP PATIENTS ADHERE TO TREATMENT WITH JUBLIA® (EFINACONAZOLE 10% TOPICAL SOLUTION) FOR TOENAIL FUNGUS

RALEIGH, N.C., JULY 11, 2018 – Ortho Dermatologics today announced the launch of JubliAppTM mobile app designed to help encourage patients to adhere to treatment with JUBLIA® (efinaconazole 10% topical solution), a topical azole used to treat fungal infections of the toenails.

April 9, 2018
ORTHO DERMATOLOGICS ANNOUNCES PUBLICATION OF PIVOTAL EFFICACY AND SAFETY DATA FOR PSORIASIS TREATMENT DUOBRIITM IN THE JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

DUOBRII Demonstrated Significant Superiority Over Vehicle As Early As Two Weeks

LAVAL, Quebec, April 9, 2018 – Ortho Dermatologics, a division of Valeant Pharmaceuticals North America, LLC (NYSE/TSX: VRX), today announced that the Journal of the American Academy of Dermatology (JAAD) published for the first time positive results from two Phase 3, multicenter, randomized, double-blind clinical trials (Studies 1 and 2) to assess the safety and efficacy of DUOBRIITM1 (halobetasol propionate and tazarotene) (IDP-118) lotion in the treatment of plaque psoriasis.2

X
X
X